Evidence map›Paper›PMID 37465456›Full record

ArticleFrontiers in cardiovascular medicine2023

Cardiac "hypertrophy" phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiography.

Aaisha Ferkh, Catherina Tjahjadi, Luke Stefani, Paul Geenty, Karen Byth, Kasun De Silva, Anita C Boyd, David Richards, Peter Mollee, Dariusz Korczyk and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Imaging Advances in Light Chain Amyloidosis.Diagnostics (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Aaisha FerkhWestmead Clinical School, University of Sydney, Westmead, NSW, Australia.
Catherina TjahjadiCardiology Department, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Luke StefaniWestmead Clinical School, University of Sydney, Westmead, NSW, Australia.
Paul GeentyWestmead Clinical School, University of Sydney, Westmead, NSW, Australia.
Karen BythWSLHD Research and Education Network, Westmead Hospital, Westmead, NSW, Australia.
Kasun De SilvaWestmead Clinical School, University of Sydney, Westmead, NSW, Australia.
Anita C BoydWestmead Private Cardiology, Westmead, NSW, Australia.
David RichardsWestmead Private Cardiology, Westmead, NSW, Australia.
Peter MolleeHaematology Department, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Dariusz KorczykCardiology Department, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Mark S TaylorDepartment of Clinical Immunology and Allergy, Westmead Hospital, Westmead, NSW, Australia.
Fiona KwokHaematology Department, Westmead Hospital, Westmead, NSW, Australia.
Eddy KizanaWestmead Clinical School, University of Sydney, Westmead, NSW, Australia.
Arnold C T NgCardiology Department, Princess Alexandra Hospital, Brisbane, QLD, Australia.
Liza ThomasWestmead Clinical School, University of Sydney, Westmead, NSW, Australia.
Princess Alexandra Hospital · AUWestmead Institute · AUWestmead Hospital · AUThe University of Sydney · AUWestmead Institute for Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Differentiating phenotypes of cardiac "hypertrophy" characterised by increased wall thickness on echocardiography is essential for management and prognostication. Transthoracic echocardiography is the most commonly used screening test for this purpose. We sought to identify echocardiographic markers that distinguish infiltrative and storage disorders that present with increased left ventricular (LV) wall thickness, namely, cardiac amyloidosis (CA) and Anderson-Fabry disease (AFD), from hypertensive heart disease (HHT). Methods: Patients were retrospectively recruited from Westmead Hospital, Sydney, and Princess Alexandra Hospital, Brisbane. LV structural, systolic, and diastolic function parameters, as well as global (LVGLS) and segmental longitudinal strains, were assessed. Previously reported echocardiographic parameters including relative apical sparing ratio (RAS), LV ejection fraction-to-strain ratio (EFSR), mass-to-strain ratio (MSR) and amyloidosis index (AMYLI) score (relative wall thickness × Results: A total of 209 patients {120 CA [58 transthyretin amyloidosis (ATTR) and 62 light-chain (AL) amyloidosis], 31 AFD and 58 HHT patients; mean age 64.1 ± 13.7 years, 75% male} comprised the study cohort. Echocardiographic measurements differed across the three groups, The LV mass index was higher in both CA {median 126.6 [interquartile range (IQR) 106.4-157.9 g/m Conclusion: Simple echocardiographic parameters differentiate between different "hypertrophic" cardiac phenotypes. These have potential utility as a screening tool to guide further confirmatory testing.

Indexed as

cardiac amyloidosiscardiac hypertrophyechocardiographyFabry diseaseinfiltrative cardiomyopathiesstrain imaging

Identifiers

PMID37465456
PMCPMC10351962
OpenAlexW4382984119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.